Published in Am J Cardiol on July 09, 2008
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med (2010) 2.21
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol (2012) 1.32
Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail (2011) 1.19
Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail (2014) 1.07
Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol (2013) 1.07
Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol (2011) 1.05
BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev (2014) 0.96
Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women. AIDS Res Hum Retroviruses (2009) 0.92
Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol (2014) 0.91
Electrocardiography patterns and the role of the electrocardiography score for risk stratification in acute pulmonary embolism. Korean Circ J (2010) 0.89
New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy. J Cardiovasc Transl Res (2013) 0.87
Natriuretic peptides in the detection of preclinical diastolic or systolic dysfunction. Clin Res Cardiol (2010) 0.87
Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract (2011) 0.86
Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases. Heart Fail Rev (2010) 0.80
A novel electrocardiographic index for the diagnosis of diastolic dysfunction. PLoS One (2013) 0.79
Diastolic dysfunction without abnormalities in left atrial and left ventricular geometry does not affect quality of life in elderly women. Exp Clin Cardiol (2011) 0.78
Perioperative management of left ventricular diastolic dysfunction and heart failure: an anesthesiologist's perspective. Korean J Anesthesiol (2017) 0.78
Potential Expanded Indications for Neprilysin Inhibitors. Curr Heart Fail Rep (2017) 0.76
Long-term outcome of patients with triphasic mitral flow with a mid-diastolic L wave: prognostic role of left atrial volume and N-terminal pro-brain natriuretic peptide. Int J Cardiovasc Imaging (2017) 0.75
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J (2006) 10.77
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr (2008) 7.91
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J (2004) 3.65
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004) 3.58
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J (2005) 3.50
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol (2007) 3.23
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 3.15
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol (2012) 3.03
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J (2008) 2.65
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care (2005) 2.59
Person-centered care--ready for prime time. Eur J Cardiovasc Nurs (2011) 2.49
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation (2007) 2.41
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation (2005) 2.39
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet (2013) 2.37
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J (2012) 2.29
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol (2002) 2.19
Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J (2005) 2.19
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med (2009) 2.05
Effects of person-centred care in patients with chronic heart failure: the PCC-HF study. Eur Heart J (2011) 2.00
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 1.98
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail (2005) 1.96
Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke (2009) 1.94
Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail (2011) 1.93
Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail (2002) 1.93
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail (2009) 1.93
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J (2012) 1.89
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J (2008) 1.84
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol (2013) 1.83
Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing). Am J Cardiol (2008) 1.79
[More stringent requirements concerning manuscripts. Declarations of potential connections and conflicts of interest published in the Lakartidningen]. Lakartidningen (2002) 1.74
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol (2006) 1.71
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70
Influence of global region on outcomes in heart failure β-blocker trials. J Am Coll Cardiol (2011) 1.69
Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J (2007) 1.69
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J (2015) 1.68